---
title: "Ipsen Advances Late-Stage Trial for New Wrinkle Treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306399090.md"
description: "Ipsen (GB:0MH6) announced an update on its Phase III clinical trial for IPN10200 (corabotase), a biological treatment for moderate to severe glabellar lines. The study, conducted in China, evaluates the efficacy and safety of a single injection compared to a placebo over a 55-week follow-up period. While no results are posted yet, the ongoing recruitment supports investor confidence in Ipsen's aesthetic medicine pipeline amidst competitive market conditions."
datetime: "2026-11-22T16:30:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306399090.md)
  - [en](https://longbridge.com/en/news/306399090.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306399090.md)
generator: "portal-rs"
---

# Ipsen Advances Late-Stage Trial for New Wrinkle Treatment

Ipsen (GB:0MH6) announced an update on their ongoing clinical study.

**Study Overview:** Ipsen is testing IPN10200, also called corabotase, in adults in China with moderate to severe lines between the eyebrows. The official title is “A Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of IPN10200 in the Improvement of the Appearance of Moderate To Severe Glabellar Lines in Adult Chinese Participants.”

The study will assess whether one dose improves the appearance of these lines and remains safe over time. The trial is important because positive results could support Ipsen’s expansion in the large and competitive market for wrinkle treatments.

**Intervention/Treatment:** Participants receive one local injection of corabotase, a biological treatment, or a placebo with no active drug. Corabotase is intended to reduce the appearance of glabellar lines by acting on selected muscles between the eyebrows.

**Study Design:** This is a Phase III treatment study with participants assigned at random to either corabotase or placebo. Participants, study doctors, and those assessing results are not told which treatment was given, helping reduce bias.

**Study Timeline:** The registry does not list a study start date, primary completion date, or estimated completion date. The record was first submitted on August 19, 2026, and was last updated on November 19, 2026, showing that recruitment information remains active.

The study is recruiting and each participant may be followed for up to 55 weeks after the single injection. That long follow-up should provide information on both the treatment’s durability and its safety, although no study results have been posted.

**Market Implications:** The update offers limited immediate evidence for Ipsen’s stock, since it reports trial progress rather than clinical results. Still, continued recruitment in a late-stage study may support investor confidence in Ipsen’s aesthetic medicine pipeline.

Investor sentiment will likely depend on future efficacy, safety, and regulatory updates. The treatment is entering a crowded wrinkle-care market, where competition from established injectable products means clear benefits and reliable results will be important.

The study is ongoing and was updated on the ClinicalTrials portal, where further details are available.

To learn more about GB:0MH6’s potential, visit the Ipsen drug pipeline page.

## Related News & Research

- [Höegh Autoliners ASA Just Missed EPS By 9.5%: Here's What Analysts Think Will Happen Next](https://longbridge.com/en/news/306385955.md)
- [Results: NKT A/S Exceeded Expectations And The Consensus Has Updated Its Estimates](https://longbridge.com/en/news/306385316.md)
- [Falcon Finance: Unlocks About 203 Million FF - Jul 2027](https://longbridge.com/en/news/306392750.md)
- [Falcon Finance: Schedules Unlock of About 203 Million FF - Jun 2027](https://longbridge.com/en/news/306392755.md)
- [Falcon Finance: Supply unlock releases about 203 million FF - May 2027](https://longbridge.com/en/news/306388616.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**